BioLuminate has completed Series A&B private financings for a total of approximately $6M, from 54 private investors. This funding was used to develop and produce the first "Prototype System" and successfully test 23 breast cancer patients at the UC San Francisco and UC Davis Medical Centers. A Series C private financing is underway now, for $33M.
This third financing is estimated to be sufficient to complete product development and progress from the prototype design to a final production system. Several "Production Systems" would be manufactured for final FDA testing at several medical centers in the US, one in Canada and one in Europe. This entire effort, including FDA approval and a market launch, is estimated to be completed within three years.